Open Label, Dose Finding and Expansion Phase IB Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (Pd L1 Antibody) in Pateints With Advanced Ovarian Cancer or Triple Negative Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 09 Jan 2019
At a glance
- Drugs Atezolizumab (Primary) ; RG 6146 (Primary)
- Indications Breast cancer; Ovarian cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 02 Jan 2019 Planned End Date changed from 9 Jan 2021 to 16 Jan 2021.
- 02 Jan 2019 Planned primary completion date changed from 9 Jan 2021 to 16 Jan 2021.
- 17 Dec 2018 Planned End Date changed from 16 Jan 2021 to 9 Jan 2021.